<SEC-DOCUMENT>0001513162-20-000126.txt : 20200617
<SEC-HEADER>0001513162-20-000126.hdr.sgml : 20200617
<ACCEPTANCE-DATETIME>20200616200544
ACCESSION NUMBER:		0001513162-20-000126
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200616
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200617
DATE AS OF CHANGE:		20200616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20967809

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body lang=EN-IN> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>UNITED STATES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>WASHINGTON, D.C.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>FORM 8-K</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>CURRENT REPORT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Pursuant to Section 13 or 15(d) of the</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Securities Exchange Act of 1934</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Date of Report (date of earliest event reported): <b>June 16, 2020</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><u><font lang=EN-US>BIOMERICA, INC.</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>(Exact Name of Registrant as Specified in its Charter)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <div align=center> <table width=633 bordercolor=transparent style=WIDTH:474.75pt cellpadding=0 cellspacing=0> <tr> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>Delaware</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" /> <td style="BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0cm; MARGIN-RIGHT:0cm' align=center><font style=FONT-SIZE:11pt lang=EN-US>001-37863</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" /> <td style="BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>95-2645573</font></p></td></tr> <tr> <td width=93 style="WIDTH:69.75pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0cm; MARGIN-RIGHT:0cm' align=center><font style=FONT-SIZE:11pt lang=EN-US>(State or Other Jurisdiction of Incorporation)</font></p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" /> <td width=83 style="WIDTH:62.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>(Commission File Number)</font></p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" /> <td width=138 style="WIDTH:103.5pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>(IRS Employer Identification Number)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>17571 Von Karman Ave.</font></p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt'><font lang=EN-US>Irvine, California 92614</font></h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>(Address of Principal Executive Offices</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Including Zip Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><u><font lang=EN-US>949-645-2111</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>(Registrant&#146;s Telephone Number,</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Including Area Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><b><font lang=EN-US>Not applicable</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>(Former Name or Former Address if Changed</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US>Since Last Report)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font lang=EN-US>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt 0cm 0pt'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings" lang=EN-US>&#168;</font><font style=FONT-SIZE:11pt lang=EN-US>&nbsp;</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings" lang=EN-US>&#168;</font><font style=FONT-SIZE:11pt lang=EN-US>&nbsp;</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings" lang=EN-US>&#168;</font><font style=FONT-SIZE:11pt lang=EN-US>&nbsp;</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings" lang=EN-US>&#168;</font><font style=FONT-SIZE:11pt lang=EN-US>&nbsp;</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0cm 0pt; LINE-HEIGHT:120%'><font lang=EN-US>Securities registered pursuant to Section 12(b) of the Act:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0cm 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm -10pt 0pt 0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm -10pt 0pt 0cm; LINE-HEIGHT:120%'><font lang=EN-US>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; LINE-HEIGHT:120%" lang=EN-US>&#168;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt -10pt 0pt 0cm; LINE-HEIGHT:120%'><font lang=EN-US>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</font><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; LINE-HEIGHT:120%" lang=EN-US>&#168;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>1</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b><font lang=EN-US>Item 7.01 Regulation FD Disclosures.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'><font lang=EN-US>On June 16, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing that it has filed for FDA Emergency Use Authorization of its unique laboratory antibody test for COVID-19.&nbsp; The Company also announced that it has filed a provisional patent on technology to allow simplified blood collection of samples. A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'><font lang=EN-US>The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b><font lang=EN-US>Item 8.01 Other Events.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'><a name=_Hlk39847039><font lang=EN-US>On June 14, 2020, the Company filed for FDA Emergency Use Authorization (EUA) for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel Coronavirus (COVID-19).</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'><font lang=EN-US>On April 21, 2020, the Company filed a provisional patent on technology to allow simplified blood collection of samples.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'><b><font style=COLOR:black lang=EN-US>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-INDENT:-18pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-INDENT:36pt'><font lang=EN-US>(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-INDENT:36pt'>&nbsp;</p> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="WIDTH:9.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>&nbsp;</font><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>Number</font></u></b></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="WIDTH:89.66%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0.7pt; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>Description</font></u></b></p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'><font lang=EN-US>99.1</font></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm -5.65pt 0pt 0cm; LINE-HEIGHT:115%'><font lang=EN-US>Press Release issued June 16, 2020.</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:left; MARGIN:0cm 21.6pt 0pt 0cm' align=left><font lang=EN-US></font></h2> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0cm 21.6pt 0pt 0cm'><font lang=EN-US>SIGNATURE</font></h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 21.6pt 0pt 0cm'><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 21.6pt 0pt 0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0cm 21.6pt 0pt 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 21.6pt 0pt 0cm' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:450pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>Dated:&nbsp; <font size=3>June 17, 2020</font></p></td> <td width=266 colspan=2 nowrap style="HEIGHT:15.75pt; WIDTH:199.65pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p></td> <td width=36 nowrap style="HEIGHT:15.75pt; WIDTH:27.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p></td> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=36 nowrap style="HEIGHT:15.75pt; WIDTH:27.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>By: </font></p></td> <td width=230 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:172.35pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>/s/ Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=36 nowrap style="HEIGHT:15.75pt; WIDTH:27.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=36 nowrap style="HEIGHT:15.75pt; WIDTH:27.3pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom /> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0cm 0cm 0pt'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt' align=center><font style=FONT-SIZE:11pt lang=EN-US>3</font></p></div></body>
<!-- EDGAR Validation Code: 093F6D1C -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head><title>Exhibit 99.1</title> </head> <body lang=EN-IN> <div style=page:WordSection1> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt 5pt; TEXT-AUTOSPACE:'><img src=logo.jpg> </p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:1.45pt 5.6pt 0pt 5pt; TEXT-AUTOSPACE:'><b><font style="FONT-SIZE:13pt; COLOR:#002c40" lang=EN-US>Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19</font></b></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <h1 style='FONT-SIZE:13.5pt; FONT-FAMILY:"Calibri","sans-serif"; FONT-WEIGHT:bold; MARGIN:0cm 5.6pt 0pt 41pt; TEXT-AUTOSPACE:; TEXT-INDENT:-18pt'><font style=FONT-SIZE:13pt><font style="FONT-WEIGHT:normal; COLOR:#002c40" lang=EN-US>-<font style='FONT-FAMILY:"Times New Roman"; FONT-VARIANT:normal; FONT-WEIGHT:normal; FONT-STYLE:normal; LINE-HEIGHT:normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style=COLOR:#002c40 lang=EN-US>This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA.</font></font></h1> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 5.65pt 0pt 41pt; LINE-HEIGHT:100%; TEXT-AUTOSPACE:; TEXT-INDENT:-18pt'><font style=FONT-SIZE:13pt><font style="COLOR:#002c40; LINE-HEIGHT:100%" lang=EN-US>-<font style='FONT-FAMILY:"Times New Roman"; FONT-VARIANT:normal; FONT-WEIGHT:normal; FONT-STYLE:normal; LINE-HEIGHT:normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><font style="COLOR:#002c40; LINE-HEIGHT:100%" lang=EN-US><strong>This test adds to the previously announced Biomerica 10-minute finger prick antibody tests already being sold outside of the US.</strong></font></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 5.75pt 0pt 41pt; TEXT-AUTOSPACE:; TEXT-INDENT:-18pt'><font style=FONT-SIZE:13pt><font style=COLOR:#002c40 lang=EN-US>-<font style='FONT-FAMILY:"Times New Roman"; FONT-VARIANT:normal; FONT-WEIGHT:normal; FONT-STYLE:normal; LINE-HEIGHT:normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></font><b><font style=COLOR:#002c40 lang=EN-US>Biomerica has filed a provisional patent on technology to allow simplified blood collection.</font></b></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:10.1pt 5.65pt 0pt 5pt; TEXT-AUTOSPACE:'><font style=FONT-SIZE:10pt><font style=COLOR:#002c40 lang=EN-US>IRVINE, CA - (June 16, 2020) - Biomerica Inc. (NASDAQ: </font><font lang=EN-US><font style="TEXT-DECORATION:none; COLOR:#0070ba">BMRA</font><font style=COLOR:#002c40>) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel Coronavirus (COVID-19). Antibody testing can be an important next step in opening the economy to tell people if they have been previously infected. This is the third COVID- 19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests, are actively being sold outside of the US and have been well received. The Company also intends to obtain a CE mark to market and sell this ELISA laboratory test outside the US.</font></font></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.6pt 0pt 5pt; TEXT-AUTOSPACE:'><font style=FONT-SIZE:10pt><font style=COLOR:#002c40 lang=EN-US>Biomerica performed testing both internally and at two external labs located in California. The data from this testing that was submitted to the FDA under the EUA application showed 100 percent specificity and zero percent cross reactivity with many common disease states. This test, which uses the ELISA microplate format, can be run on existing open system equipment found in most hospitals and clinical laboratories in the US and outside the US and uses a modified, trimeric spike protein from the SARS-CoV-2 virus. This spike protein is known to be the target of neutralizing antibodies, which can help prevent the virus from entering the cells.</font><font style="POSITION:relative; COLOR:#002c40; TOP:-3.5pt" lang=EN-US>1 </font><font style=COLOR:#002c40 lang=EN-US>Persons who are no longer infectious and have tested positive for the antibodies, can possibly be cleared to return to work as they may have a lower likelihood of reinfection and/or spreading the virus. Antibody tests will also help in better understanding the virus including how long antibodies stay in the body and if they help in immunity as well as how many people have been infected in the population as a whole. Further, this type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.</font></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.75pt 0pt 5pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>This ELISA laboratory test was developed by Biomerica and will be manufactured exclusively at Biomerica&#146;s manufacturing facility located in Irvine, California, using existing high-throughput, automated equipment. Biomerica has extensive experience manufacturing similar serology ELISA tests for other diseases.</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.6pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; PADDING-BOTTOM:0px; TEXT-ALIGN:justify; MARGIN:2.05pt 5.7pt 1pt 5pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>"We are working to provide significant, high specificity and meaningful diagnostic solutions for the novel Coronavirus," said Zack Irani-Cohen, CEO and Chairman of Biomerica. "Our ELISA test will be unique in the market place by simplifying the blood sample collection process in a proprietary way. We have been working with the FDA, who has been very responsive, and we&#146;re looking forward to a quick review for this submission. I&#146;m very proud of our team members who are working around the clock to develop, validate and attain regulatory clearance on these COVID-19 diagnostic solutions that benefit patients, healthcare workers and society&#148;.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:ideograph-numeric' align=center>1</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:ideograph-numeric' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div></div> <div style=page:WordSection2> <h2 style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; FONT-WEIGHT:bold; TEXT-ALIGN:justify; MARGIN:0.05pt 0cm 0pt 5pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>About Serology Tests</font></h2> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.1pt 5.65pt 0pt 5pt; LINE-HEIGHT:98%; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>Serology tests look for the presence of antibodies, which are specific proteins made in response to infections. The antibodies detected by serology tests indicate that a person has had an immune response to the novel Coronavirus (SARS-CoV-2), whether symptoms developed from infection or the infection was asymptomatic. Antibody test results are important in detecting infections with few or no symptoms.</font><font style="FONT-SIZE:7pt; POSITION:relative; COLOR:#002c40; LINE-HEIGHT:98%; TOP:-3.5pt" lang=EN-US>2</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.1pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt 13.9pt; TEXT-AUTOSPACE:; TEXT-INDENT:-8.95pt'><font style="FONT-SIZE:9pt; COLOR:#002c40; LETTER-SPACING:-0.1pt" lang=EN-US>1.<font style='FONT:7pt "Times New Roman"'>&nbsp; </font></font><font style="FONT-SIZE:9pt; COLOR:#002c40" lang=EN-US>medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20047365. Accessed 15Jun20</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0cm 0pt 13.9pt; TEXT-AUTOSPACE:; TEXT-INDENT:-8.95pt'><font style="FONT-SIZE:9pt; COLOR:#002c40; LETTER-SPACING:-0.1pt" lang=EN-US>2.<font style='FONT:7pt "Times New Roman"'>&nbsp; </font></font><font style="FONT-SIZE:9pt; COLOR:#002c40" lang=EN-US>Emerging Microbes &amp; Infections 2020, VOL. 9 Molecular and serological investigation of 2019-nCoV infected patients.</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.1pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <h2 style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; FONT-WEIGHT:bold; TEXT-ALIGN:justify; MARGIN:0.05pt 0cm 0pt 5pt; LINE-HEIGHT:12.75pt; TEXT-AUTOSPACE:'><font style=FONT-SIZE:10pt><font style=COLOR:#002c40 lang=EN-US>About Biomerica (NASDAQ: </font><font lang=EN-US><font style="TEXT-DECORATION:none; COLOR:#0070ba">BMRA</font><font style=COLOR:#002c40>)</font></font></font></h2> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.65pt 0pt 5pt; TEXT-AUTOSPACE:'><font style=FONT-SIZE:10pt><font style=COLOR:#002c40 lang=EN-US>Biomerica, Inc. (</font><font lang=EN-US><font style="TEXT-DECORATION:none; COLOR:#0070ba">www.biomerica.com</font><font style=COLOR:#002c40>) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in <font style=LETTER-SPACING:-0.15pt>home </font>and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development.</font></font></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <h2 style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; FONT-WEIGHT:bold; TEXT-ALIGN:justify; MARGIN:0.05pt 0cm 0pt 5pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>About InFoods&#174;</font></h2> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.5pt 0pt 5pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>The Biomerica InFoods&#174;IBS product is designed to allow physicians to identify patient specific foods(e.g.eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods&#174; diagnostic products. Since the InFoods&#174;product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.6pt 0pt 5pt; TEXT-AUTOSPACE:'><font style=COLOR:#002c40 lang=EN-US><font style=FONT-SIZE:10pt>The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s COVID-19 test, FDA clearance, EUA clearance, the rapidity of testing results, uniqueness of a product, pricing of the Company&#146;s test kits,demand for international orders, availability of the Company&#146;s COVID-19 test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company&#146;s COVID-19 test; regulatory approvals necessary prior to commercialization of theCompany&#146;sCOVID-19 test; availability of the Company&#146;s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its rapid test technology. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business mode land expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 5.6pt 0pt 5pt; TEXT-AUTOSPACE:'>&nbsp;</p></font></div> <div style=page:WordSection3> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 5pt; TEXT-AUTOSPACE:'><b><font style=FONT-SIZE:10pt lang=EN-US>CONTACT INFORMATION</font></b></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 353.5pt 0pt 23pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>Company Spokesperson</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 353.5pt 0pt 23pt; TEXT-AUTOSPACE:'><font style="FONT-SIZE:10pt; COLOR:#002c40" lang=EN-US>949-645-2111</font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0cm 0cm 0pt 23pt; LINE-HEIGHT:12.75pt; TEXT-AUTOSPACE:'><font lang=EN-US><font style="FONT-SIZE:10pt; TEXT-DECORATION:none; COLOR:#0070ba">http://www.biomerica.com</font></font></p> <p style='FONT-SIZE:10.5pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt 23pt; LINE-HEIGHT:12.75pt; TEXT-AUTOSPACE:' align=center><font style=FONT-SIZE:11pt>2</font></p></div></body>
<!-- EDGAR Validation Code: 8FCD5A17 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0^P17AI9@  34T *@    @ ! $2  ,
M   !  $   $Q  (    F    /@$R  (    4    9(=I  0    !    >
M .17:6YD;W=S(%!H;W1O($5D:71O<B Q,"XP+C$P,#$Q+C$V,S@T #(P,C Z
M,#8Z,38@,38Z,34Z-3(   60 P "    %    +J0!  "    %    ,Z2D0 "
M     S0T  "2D@ "     S0T  "@ 0 #     0 !        ,C R,#HP-CHQ
M-B Q-CHQ-#HS,  R,#(P.C V.C$V(#$V.C$T.C,P      8! P #     0 &
M   !&@ %     0   3(!&P %     0   3H!*  #     0 "   " 0 $
M 0   4(" @ $     0  #F8         8     $   !@     ?_8_]L 0P (
M!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W
M*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\
M$0@ ) #I P$A  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'
M" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R
M@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*
M4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S
M]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41
M  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC
M,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:
M  P# 0 "$0,1 #\ ]^HH ** "B@!:* $HH ** "HY((I1B1%;ZT#3:U15?1M
M-D^_90-]4!J!O#6B.<MI=H?K$*#98FJMI$3>$?#S=='L_P#OR*A;P1X:?KI%
MM_P%<?RH-8YAB8[2*TGPZ\+2?\PS;_NRN/ZU2E^%OAY_]6+J'_<F/]<TK)G5
M#.\9'1RN49?A/:_\NVL7L1[;L-_+%9T_PSU^ $V7B$OZ!F>/^1-%NQW4\^4E
M:M"YFS^'/B#IO,5S=S*.\-V6_0G/Z5F2^*O&ND-MNKJ\AP<8N(!S^+"A\RW/
M1HQRS&:16OW%FW^*?B.''F-:SXZ[XL9_(BMFT^,,HP+O248=VBEQ^A']:7,1
M7X=I2UI2M^)T-A\4O#UV0L[3VC'_ )ZQY'YKFNKL=5L-3B\RRO(;A>YC<''U
MJKGSN+RVOA=9K3N7**#SSSCXF^+-3T*ZL+72[KR'=&DEPBMD9 7J#Z-4ECI?
MCZ_TZ"Z_X26&+SHED"&W7*Y&<'Y:]&,:-.C&<U=L\R4ZU2O*$'9(YRZ\:>+O
M#'B+^SM2NX+_ &,NY!&N'!YX( (./\FK/C+QIKUMXRDTO2+TQ1IY<001JV7(
M![C_ &@/PKHCA:4IJ26C5_R.9XNM&#BWJG8LZ]\0=5.KKH/A]%EN480/<,@9
MI)!P=HZ 9[GWK6A\->.9HA)<^+%AE/)2.$,!^/%82A1H07.KMF\9UL1)\CLD
M<YK/B+QGX)U2&&_OX;Z&0;T+1C:X!Y' !!_QJ_XR\>:A'8:(^BS-;S7L/GNN
MU68 X"KR/7=^5:K#4JDH3BM&9O%5:<9PD]42?#?Q?JVLZU=V&K79F(AWQAD5
M2I! (X ]?TKNO$.N6_A[1I]0N3D(,(F>7<]%%<N)H*.(]G#K8Z\-B'+#^TF]
M4>+IX_\ %]S=1(FHLGVA\1J(4QRV.,CIGBMSQ1XQ\0Q>-)-(TG4"B!XX$'EH
M<N0,G)'J:]"6$HJ:5M+/]#SHXNLX-WUNC>_LCXE'_F/Z?_WP/_C=,G_X330-
M.OM4U?6[::"&V?8D2#)D/RH3\@X!.:XE+#S?+&.K.QK$Q7/*6B,7PEJGC7Q:
MUUY&O+ MN%W,]NAR6SQ]WVK1UZ/Q[X=TR74CXA@N88<&1?)4$ G' *^];3CA
MXUO9<IE"6)E1]LI&>/B3JUSX*O)V*0ZA%/%$D\:##!LD\'(SA3^=2:/\0M1T
M[PK/J>K3F]N9YS#9PE50?* 68D#I\P_2F\%"SCUN2L=/F4GM8GT6?Q[XN@^W
MQZG#IUDQ(3$0^;_=&"<?4TNOQ^./"FG'4_\ A(4O+>-@)%:)<C)P."/4CO4?
M[,JGLN7RN7_M+I^VYOD=+X"\63^*M+FDNH4CN+=PCLGW7R."/2L[Q]XSN=+E
M@T;16W:I.R[BJAC&#T&/[Q_E]:PCAX_6/9]$=$L3+ZM[3JS$\">-=:O?%8TS
M6;LRK(CHJ-&J[9%Y[#T!%>K/%'*A61%=3U##(I8VE&E5M'9HO 5YU*?,WJF<
MUJOP_P##VJ*Q-D+:4_\ +2W.P_ET/XBO._$/PQU/2T>XT]_MUN.2H7$BCZ=_
MP_*N)Q/L,KSJ<)*E7=UW['"D$'!&"#R#4D%Q-:S++;S/%(O1XV*D?B*@^PE&
M%2-GJF>C>$?B9=1W45CK;^="Y"K<XPR'_:]1[]?K7K6\5I'5'P6;X!86O:'P
MO8\+\=-)X@^([6$# L'CM(R>@/?/XL:[9O#_ ,0!;^6GB:U  P (@OZA*]>I
M.E3ITXU%?0^.I0K5*E25-VU.'\.30Z?X[6WU^R-[?_:O+,[S%MDF<!L?Q=NO
M2J.GW7]I>.;C56&Y(I)KX^P0,Z_R45U<NLI=.70Y.;W5'K?4U_A/:"[\737<
MOS-! S@GKN8@9_(FO;Z\S,7>M;LCU<M5J-^[/%/BU>_;/%-M8Q?,;>$ @==[
MG./RVU'9V?\ :7Q.TW3%.^'31'#G_KBN6_-P?SKNI^Y0C?LV<%3W\1+S:0::
M?^$>^,+Q,=L;7;I@]-L@)7_T):L:Y>7/Q&\:0Z58.1IMLQ_>#IM'WI/Z#\/6
MDTN=5GTB-2?(Z"ZR(I+:VF^+-I86ZA+/3F1$'95B3><_B#6+HEG>^*_&LDEG
M<_9IY)9+H38SY?.1^I K2,DHN<ND492BY24(]9?D>B?\(=XQQC_A,9/^^#_C
M67XY2_T/P%#INH:D]]=W5UEI6S]Q><#/8$+^=<5*I2J58QA&SN=U6E4ITI2E
M*^A1\#V/C&UT$W6AQV'V:Z<OF?[YQ\OY<5F^*M9\1O?)I/BJ:2VM3AVCM8U(
M89X(YYZ>O:NI*A.NVOB1RMUX4$G\(GC6#3-*T71=-TAF>WF0WKR.?FD+ !2?
M3@'BL37U,$.DV'/[FR1R#_>D)D/Z,H_"MJ#;C%O?5F%9)2DH[:(^A=)LDT[2
M+.S3 6"%4^N!577]5T33K5(]<E@6"8X5)DWAB.>F#TXKP4I3J>[N?0-PITO>
MV,?4?$VA>'?"C:II4=MLN"1;I#'Y8E?IG&!P,<GVKSCPZGB.#56\1?\ "/S:
ME-< O'+(" "?XA^'2O1P\%&G*55V;T/.Q,W*I&-)72U,B^N;_2?&2ZG=6+65
MQ]H%UY!]"V3CV/-?1,$J3P1S1MN1U#*P[@U&8)6A*/8K+6U*<6245YIZIXC\
M4[&SL_$T<EL%62XB\R9%_O9(S^/]*X>H>Y^CY5.4\'3<NQT/A3PG>^);] D;
M)9(P,TY' 'H/4U] >55QT1\UQ!BH5*ZIQ^S^IY+'X \70>(6UJ&73A=&9Y@7
MD+ %L]MOO6^]G\3'0J-0TM,C[RCD?FM>I4KX:HTY+8^&IT,3334>IGZ;\--2
MM6O-3N[Z*XU5XY/( 8[1(X(WLQ&3C.>G6G^#?AS>Z5=WSZNT#17%JUN!"Y)P
MV,]0,<"E/&QE"27E8<,#)2BW\RE:> /%7AC5FO-!O;65<%?G.TLOHRD8_(UN
M22_$J>/RUM])@)&/,4\C\R?Y45*V'K-3GHQTZ.(HIPAL0>'_ (<3VFIG6=;N
MUOK\,94C!.WS.H+,>3S[5+X'\%:EH>NWNJ:M) \TR$(8G+<LV6)R!Z#\ZBIB
MXSC);:)(JG@Y0E%ONVREXX^'VJ:]XB.HZ<ULJ21*'\URIW#CL#QC%=)X(\)+
MX6TADEV/?3G=/(O3V4>P_J:57%J6'5);E4L(XXAU7L<M9^ M?AU36M2E>T,]
MY#,L.)6^5Y#U/R]E+52T7P%XS\/W3W.FW.GQ3.GEEBV[C(/=?:M_K=%IQEL[
M(Y_J=9-2CNKLW/L7Q._Z">F_]\K_ /$50\1^#/%WB.VTX7ES92S6Z/YCE]H+
M,W8!?[H7]:SA5PU.:E!&DZ.)J0<9,] T#3CI&@6.GMC=!"J/MZ%L<G\\UQOQ
M \%:KXGU:UN;!K81Q0[&\URISDGL#QTKGH5E"O[1^9TUZ#G05->1CZY\-M=U
M._MS%):+;6]M#;IND.0%4 _P^NXUL^,?AN=<GCO--N(X;A(EB:.4':P48!R.
MAQQ75]>47!KH<GU"3C._42SA^)5C;); Z;<*@VK)*V6Q]>,_C5.?X?\ B'Q-
MJ27?B;581&@P([<$E1Z#@ ?7FI5?#TGSTUJ6Z&(JQY*CT'W/P^U/5O$-I]N-
MM#H=H!'#;Q2,6$8[=.K=SGO[5Z7'&D4:QHH5% 55 P !7/B*ZJ*,5T_,Z<-0
M=-RE+=G!_$'P1>^)KNSNM.:!98D:.7S6*Y7.5Q@'U-=/X8L[W3?#EE9:BT9N
M+=/+)C;(('"]?;%.I6C.A&'5"I4)0Q$I]&7;W4K+3HO-O+N&!/[TCA?YUQVJ
M?$19=UOX<L+C4KCH)%B;RU/\S^GUKD/:P>"=9\TM(K=G'+X"\5^(KY[[4]D#
MS-EGG?G\%7./IQ77Z-\*](L&66_D>^D'\+?*F?H.OXFDH]SVL;G4:</8X79:
M7.Y@@BMH5A@B2.-!A408 'TJ3\*9\PVY.[%HH$%% !10 44 %% !10 44 %%
M "=Q10 4W<:8TKAN-4-3OY;. O&$)_VA18N$%*5F<8/&>JW%Y]G'D1*?XD3G
M]2171Q:4^H1J]WJFH2 ]4641#_QP*?UH1V3A&E#FBM2Q!X3T*"7S1IL,DO7S
M)AYC?FV36LD:1H%1%51T &*1R5:]2H_>9)109!10!__9_]L 0P # @(# @(#
M P,#! ,#! 4(!04$! 4*!P<&" P*# P+"@L+#0X2$ T.$0X+"Q 6$!$3%!45
M%0P/%Q@6%!@2%!44_]L 0P$#! 0%! 4)!04)% T+#104%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@ ) #I
M P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*"__$
M +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$
M P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "
M$0,1 #\ _5&DKY"_;F_:$\6?"?6?"VD^$-8_LFYN()KJ\*P1REEW*L0PZMCE
M9/3]*L^%? G[2/BSPKIFL?\ "U[&Q^WVD5TMO)IL6^,.@;:Q$749 /OFO:CE
M<OJ\,34J1C&5[7OT]$>%+-H?6)X:G3E*4-[6_5GUKC\J.M?G=X@_:<^-?P)^
M*Q\+^*=9L/%AMY(O-@CMXPL\;@,-CHB,K%3P".O8CKK_ +2_[3GQ&T/X^7?A
M'P3KS6%K";6S2VCMH9-]Q(JL>60G.9 N,X^6NN.08F=2,(R34ES)]+:>7F<<
MN(L+&G*<HR33Y;=;Z^?D??5%?#_Q<_;$\92>.H/AS\-(8[_6()5TV;5YH5DE
MN;I?E?RT.$4!@<LP(X)  &3W&F_!#]H34[..XU7XSQZ=>L-S6]K8+(B'KC<
MF?RQ]:YI95*C",\14C#FV3O>WR1U1S>%:<H8:G*=M[6M^+1]4_SHK\^?B5\:
M/CQ^R[XRL+'Q)XCLO%6G72>?;M-;)Y<Z*0'4E55U89'<@9!R:ZO]I?\ :U\2
M6GAOX;S> KV31[_Q#9?VE<0B&.:0*Q58X\.I!^?S!D 9VUM'(\1.5-4Y)QGL
M^GS,'G^&A&HZD7&4-UU/MJBOB[]BC]HSQI\2_B%KOASQGK+:FZV/VFU62WBB
M,;)(JNOR(N2=XR#TVU],_&3XIZ7\&_ &I>)M4.Y;==D%N&P]Q,P^2-?<GOV
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MIFNJ>3RI5_JTJT>?337_ "*I<2UI4/K-.-3D[W_X)]$S?LY_#*;E_ ^AD_\
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MCM*I(_0BBBJ.FC%.=FCYX7]ICQEJ^NC35-A81M_RUMK<EQ_WVS#]*]<T_P
MS^,+6*?6O%WB2\23K!!>)9I],V\<;?F:**74^M=*G3PRG"*3[VU-32_V>OAW
MI=X+M?"UC>7F<_:M14WDV?7?*6;/XUWEK9V]E"L5O!'!&O 6-0 /PHHH/DL1
5B*U:7[R;?JVRT*6BBI.0**** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
